Physician profile
Christopher Holthof
NPI 1386160182
$541.46
in general payments reported to CMS, 2019-2025
15 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $73.37 · 2023: $177 · 2024: $15.27 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $95.94 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $79.70 | 2023 | |
| Boston Scientific Corporation | $64.36 | 2021-2025 | Watchman Flx |
| Alexion Pharmaceuticals, INC. | $40.96 | 2023-2025 | Soliris, Ultomiris |
| Novo Nordisk INC | $40.40 | 2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.90 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $28.72 | 2023-2024 | Dificid, Zerbaxa, Recarbrio |
| Chiesi USA, INC. | $27.55 | 2022 | |
| Pfizer INC. | $26.13 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.39 | 2025 | Eliquis |
| Neurelis, INC. | $21.19 | 2025 | Valtoco |
| Amgen INC. | $18.72 | 2021 | |
| Jazz Pharmaceuticals INC. | $17.51 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.20 | 2023 | |
| Abbvie INC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Holthof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.